Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001193125-20-078390
Filing Date
2020-03-19
Accepted
2020-03-19 09:02:16
Documents
11

Document Format Files

Seq Description Document Type Size
1 424B3 d810736d424b3.htm 424B3 3148386
2 GRAPHIC g810736g01w28.jpg GRAPHIC 48985
3 GRAPHIC g810736g02s37.jpg GRAPHIC 39416
4 GRAPHIC g810736g03k44.jpg GRAPHIC 56120
5 GRAPHIC g810736g04v17.jpg GRAPHIC 42801
6 GRAPHIC g810736g05q91.jpg GRAPHIC 28925
7 GRAPHIC g810736g06z11.jpg GRAPHIC 28543
8 GRAPHIC g810736g07m12.jpg GRAPHIC 30329
9 GRAPHIC g810736g21x30.jpg GRAPHIC 54004
10 GRAPHIC g810736g59u12.jpg GRAPHIC 24774
11 GRAPHIC g810736g82w04.jpg GRAPHIC 49386
  Complete submission text file 0001193125-20-078390.txt   3705534
Mailing Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862
Business Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862 978 671-8001
Lantheus Holdings, Inc. (Filer) CIK: 0001521036 (see all company filings)

EIN.: 352318913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-234627 | Film No.: 20726586
SIC: 2835 In Vitro & In Vivo Diagnostic Substances